ASCO GI 2023 | Targeting local recurrence in pancreatic adenocarcinoma with proton therapy

Pancreatic adenocarcinoma is associated with a poor prognosis and a 5-year survival rate of 10%. Benjamin Adam Weinberg, MD, Georgetown University, Washington, DC, discusses the results of PROTON-PANC (NCT03885284), a Phase I trial of proton therapy in adjuvant pancreatic cancer. Out of nine patients enrolled, only one dose-limiting adverse event in the form of neutropenia. Overall, proton therapy did not delay the chemotherapy and no local recurrence was observed in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.